Nasopharyngeal Cancer clinical trials

Explore recruiting nasopharyngeal cancer clinical trials.

Recruiting nasopharyngeal cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nasopharyngeal Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II study evaluating the efficacy of Nivolumab in the treatment of patients with nasopharyngeal cancer who progressed during or after platinum-based chemotherapy

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer. POINT study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

Spain, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

Italy, Spain, France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Nasopharyngeal Cancer trials by city

Nasopharyngeal Cancer clinical trials

Recruiting nasopharyngeal cancer studies right now

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Trop2-targeted immunoPET Imaging of Solid Tumors

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

U87 CAR-T in Patients With Advanced Head and Neck Tumors

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy